Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Teva- Pharmaceutical Industries Ltd. 30/04 15,510 USD
-0,45% 		-0,45%
vlag TherapeuticsMD Inc 30/04 1,240 USD
+0,81% 		+0,81%

Nieuws over “Farmaceutische Producten: Generisch”

17/04 · Hikma acquires Novugen's FDA-approved ANDA for trametinib · Persbericht

17/04 · Hikma acquires Novugen's FDA-approved ANDA for trametinib · Persbericht

7/04 · Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States · Persbericht

7/04 · Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention · Persbericht

31/03 · New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable · Persbericht

27/03 · Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 · Persbericht

27/03 · Teva Releases Q1 2025 Aide Memoire · Persbericht

27/03 · Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia · Persbericht

27/03 · Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM · Persbericht

3/03 · Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March · Persbericht

27/02 · 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals · Persbericht

25/02 · Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder · Persbericht

22/02 · Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease · Persbericht

21/02 · Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. · Persbericht

18/02 · Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) · Persbericht

18/02 · Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) · Persbericht

Mijn selecties